Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and
either kill them or deliver cancer-killing substances to them without harming normal cells.
Drugs used in chemotherapy uses different ways to stop cancer cells from dividing so they
stop growing or die. Combining gemtuzumab ozogamicin with chemotherapy may kill more cancer
cells.
PURPOSE: Phase II trial to study the effectiveness of gemtuzumab ozogamicin with or without
chemotherapy in treating older patients who have acute myeloid leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC